• Fasenra reduces rescue medication use in asthma

    4 days ago - By Healio

    Fasenra reduced daily rescue medication use by day 3 in patients with severe, uncontrolled asthma with eosinophilic inflammation, according to findings presented at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting.
    Fasenra , a subcutaneous injection, was previously approved by the FDA for additional maintenance treatment of severe eosinophilic asthma in patients older than 12 years.
    Researchers pooled data from two phase 3 studies with 2,510 patients aged 12 to 75 years with two or more exacerbations in the year before enrollment, and
    Read more ...